Trials / Completed
CompletedNCT02655757
Effect of Sitagliptin on Progression of Coronary Intermediate Lesion
Effect of Sitagliptin on Progression of Coronary Intermediate Lesion in Patients With Coronary Heart Disease Complicated With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Li Bo · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on Progression of Coronary Intermediate Lesion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sitagliptin | 5 mg, 1 tablet per day for 12 months |
| DRUG | Placebo | Placebo,1 tablet per day for 12 months |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2017-02-02
- Completion
- 2017-03-10
- First posted
- 2016-01-14
- Last updated
- 2018-01-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02655757. Inclusion in this directory is not an endorsement.